Breast Cancer Research and Treatment

, Volume 65, Issue 1, pp 11–21 | Cite as

Downregulation of Gelsolin Correlates with the Progression to Breast Carcinoma

  • Janet S. Winston
  • Harold L. Asch
  • Paul J. Zhang
  • Stephen B. Edge
  • Andrew Hyland
  • Bonnie B. Asch
Conference Report

Abstract

The actin cytoskeleton underlies several normal cellular functions and is deranged during carcinogenesis. Gelsolin, a multifunctional actin-binding protein, is downregulated in several types of tumors and its abnormal expression is one of the most common defects noted in invasive breast carcinoma (ICA). This study utilizes immunohistochemistry to examine the expression of gelsolin in 95 ICA, 59 ductal carcinoma in situ (DCIS) and 36 benign lesions, including 17 atypical ductal hyperplasia (ADH). Cytoplasmic staining was scored as positive, reduced or negative. Gelsolin expression was then correlated with patient’s age, tumor size, histologic grade and lymph node status. All unremarkable breast biopsies, 88% of ADH, 44% of DCIS and 28% of ICA were positive for gelsolin. This represents a significant difference among the groups (p=<0.0001) and the trend towards reduced gelsolin with the progression to ICA is significantly linear (p=<0.0001). For invasive carcinoma, patients older than 44 years were significantly more likely to have decreased expression of gelsolin than patients 44 years old and younger (p=0.007). Bivariate analysis showed no correlation of gelsolin expression with lymph node status (p=0.62), tumor size (p=0.10), histologic grade (p=0.42), estrogen receptor status (p=1.0) or other clinicopathologic parameters. In clinical follow-up, there were 18 breast tumor related deaths within a median follow-up time of 4.2 years. Survival analysis indicated that the level of gelsolin expression may be associated with survival (p=0.06). In summary, the frequency of gelsolin deficiency increases significantly with progression from ADH to DCIS to ICA. Additionally, gelsolin expression may be an independent marker of prognosis.

gelsolin breast atypical ductal hyperplasia carcinoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Janmey PA, Chaponnier C: Medical aspects of the actin cytoskeleton. Curr Opin Cell Biol 7: 111-117, 1995Google Scholar
  2. 2.
    Yin HL: Gelsolin: calcium-and polyphosphoinositideregulated modulating protein. Bioessays 7: 176-179, 1988Google Scholar
  3. 3.
    Kwiatkowski DJ, Westbrook CA, Bruns GAP, Morton CC. Localization of gelsolin proximal to ABL on chromosome 9. Am J Hum Genet 42: 565-572, 1988Google Scholar
  4. 4.
    Ohtsu M, Sakai N, Fujita H, Kashiwagi M, Gasa S, Shimizu S, Eguchi Y, Tsujimoto Y, Sakiyama Y, Kobayashi K, Kuzumaki N: Inhibition of apoptosis by the actin-regulatory protein gelsolin. EMBO J 16(15): 4650-4656, 1977Google Scholar
  5. 5.
    Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, Chu K, McGarry TJ, Kirschner MW, Koths K, Kwiatkowski DJ, Williams LT: Caspase-3-generated fragment of gelsolin: Effector of morphological change in apoptosis. Science 278: 294-298, 1997Google Scholar
  6. 6.
    Tanaka M, Mullauer L, Ogiso Y et al: Gelsolin: A candidate for suppressor of human bladder cancer. Cancer Res 55: 3228-3232, 1995Google Scholar
  7. 7.
    Vandekerckhove J, Bauw G, Vancompernolle K, Honore B, Celis: Comparative two-dimensional gel analysis and microsequencing identifies gelsol in as one of the most prominent downregulated markers of transformed human fibroblasts and epithelial cells. J Cell Biol 111: 95-102, 1990Google Scholar
  8. 8.
    Moriya S, Yanagihara K, Fujita H, Kuzumaki N: Differential expression of HSP90, gelsolin and GST-πin gastric carcinoma cell lines. Moriya Int J Oncol 5: 1347-1351, 1994Google Scholar
  9. 9.
    Asch HL, Head K, Dong Y, Natoli F, Winston JS, Connolly JL, Asch BB: Wide spread loss of gelsolin in breast cancers of human, mice and rats. Cancer Res 56: 4841-4845, 1996Google Scholar
  10. 10.
    Chapponier C, Gabbiani G: Gelsolin modulation in epithelial and stromal cells of mammary carcinoma. Am J Pathol 134: 597-602, 1989Google Scholar
  11. 11.
    Medina D, Kittrell FS, Oborn CJ, Schwartz M: Growth factor dependency and gene expression in preneoplastic mousemammary epithelial cells. Cancer Res 53: 668-674, 1993Google Scholar
  12. 12.
    Dong Y, Medina D, Ip C, Ip M, Guzman R, Asch HL, Asch BB: Concurrent deregulation of gelsolin and cyclin D1 in the majoriy of breast cancers in human and rodents. Int J Cancer 81: 930-938, 1999Google Scholar
  13. 13.
    Dosaka-Akita H, Hommura F, Fujita H, Kinoshita I, Nishi M, Morikawa T, Katoh H, Kawakami Y, Kuzumaki N: Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res 58: 322-327, 1998Google Scholar
  14. 14.
    Shieh D, Godleski J, Herndon JE, Azuma T, Mercer H, Sugarbaker DJ, Kwiatkowski DJ: Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: The role of gelsolin expression. Cancer 85: 47-57, 1999Google Scholar
  15. 15.
    Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW: Gene expression profiles in normal and cancer cells. Science 276: 1268-1272, 1997Google Scholar
  16. 16.
    Mielnicki L, Ying A, Head K, Asch HL, Asch BB: Epigenetic regulation of gelsolin expression in human breast cancer cells. Expt Cell Res 249: 161-176, 1999Google Scholar
  17. 17.
    Asch HL, Winston JS, Edge SB, Stomper PC, Asch BB: Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion. Breast Cancer Res Treat 55: 179-188, 1999Google Scholar
  18. 18.
    Page DL, Dupont WD, Rogers LW, Rados MS: Atypical hyperplastic lesions of the female breast: A long-term follow-up study. Cancer 55: 2698-2708, 1985Google Scholar
  19. 19.
    Rosen PP, Braun Jr DW, Kinne DW: The clinical significance of pre-invasive breast carcinoma. Cancer 46: 919-925, 1980Google Scholar
  20. 20.
    Page DL, Dupont WD, Rogers LW, Landenberger M: Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 49: 751-758, 1982Google Scholar
  21. 21.
    Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA: Continued local recurrence 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breat treated only by biopsy. Cancer 76: 1197-1200, 1995Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Janet S. Winston
    • 1
  • Harold L. Asch
    • 1
    • 2
  • Paul J. Zhang
    • 3
  • Stephen B. Edge
    • 4
  • Andrew Hyland
    • 5
  • Bonnie B. Asch
    • 1
    • 2
  1. 1.Department of PathologyRoswell Park Cancer InstituteBuffalo
  2. 2.Section of Experimental PathologyRoswell Park Cancer InstituteBuffalo
  3. 3.Currently at Department of PathologyHospital of the University of PennsylvaniaPhiladelphia
  4. 4.Division of Surgical OncologyRoswell Park Cancer InstituteBuffaloUSA
  5. 5.Department of Cancer Prevention, Epidemiology and BiostatisticsRoswell Park Cancer InstituteBuffaloUSA

Personalised recommendations